We found that Ki20227 treatment significantly reduced the percentage of Ki67+ proliferating tumor cells at 4wkPO relative to primary site tumors from untreated VE mice (Figure 5A), and that by 6wkPO this translated into significantly smaller tumor size (Figure 5B). The gene discussed is MKI67; the disease is neoplasm.